Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers

JAMA

Volumn 306, Issue 1, 2011, Pages 70-78

  Simon, Albane ^a,c   Warszawski, Josiane ^d,e,f   Kariyawasam, Dulanjalee ^a,c   Le Chenadec, Jerome ^d   Benhammou, Valerie ^d   Czernichow, Paul ^a   Foissac, Frantz ^a,b   Laborde, Kathleen ^a   Tréluyer, Jean Marc ^a,b   Firtion, Ghislaine ^g   Layouni, Inès ^h   Munzer, Martine ⁱ   Bavoux, Françoise ^g   Polak, Michel ^a,c   Blanche, Stéphane ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b EA 36 20   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f BICÊTRE HOSPITAL   (France)

^g Hôpital Intercommunal ^*  (France)

^h CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

ⁱ REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PRASTERONE SULFATE; ZIDOVUDINE; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ADRENAL DISEASE; ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ANTIVIRAL THERAPY; ARTICLE; CARDIOGENIC SHOCK; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPONATREMIA; INFANT; MALE; MONOTHERAPY; NEWBORN; NEWBORN SCREENING; PERINATAL DRUG EXPOSURE; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DISEASE TRANSMISSION; FRANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; PREGNANCY; PREGNANCY COMPLICATION; VERTICAL TRANSMISSION;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL INSUFFICIENCY; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMIDINONES; RETROSPECTIVE STUDIES; RITONAVIR; ZIDOVUDINE;

EID: 79960032646     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.915     Document Type: Article

References (34)

1. Coovadia H. Current issues in prevention of mother-to-child transmission of HIV-1. Curr Opin HIV AIDS. 2009;4(4):319-324.
2. Prise en charge médicale des personnes infectées par le VIH: recommandations du groupe d'experts, rapport 2010. http://www.sante.gouv. fr/rapport-2010-sur-la-prise-en-charge-medicale -des-personnes-infectees-par-le- vih-sous-la-direction-du-pr-patrick-yeni.html. Accessed May 19, 2011.
3. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. http://aidsinfo.nih. gov/ContentFiles/PerinatalGL.pdf. Accessed May 19, 2011.
4. Lyall EG, Blott M, de Ruiter A, et al; British HIV Association. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. HIV Med. 2001;2(4):314-334.
5. Chiappini E, Galli L, Tovo PA, et al. Use of postnatal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV is increasing in Italy. Clin Infect Dis. 2009;49(10):1618-1619.
6. Haile-Selassie H, Townsend C, Tookey P. Use of neonatal post-exposure prophylaxis for prevention of mother-to-child HIV transmission in the UK and Ireland, 2001-2008 [published online January 20, 2011]. HIV Med. doi:10.1111/j.1468-1293.2010.00902.x.
7. Nielsen KN, Watts H, Gonçalves Veloso V, et al. Phase III randomized trial of the safety and efficacy of 3 neonatal ARV regimes for prevention of intrapartum HIV-1 transmission: NICHD HPTN 040 /PACTG 1043 [abstract 124 LB]. Paper presented at: 18th Conference on Retrovirus and Opportunistic infection (CROI); March 2, 2011; Boston, MA.
8. Croxtall JD, Perry CM. Lopinavir/ritonavir: a review of its use in the management of HIV-1 infection. Drugs. 2010;70(14):1885-1915.
9. Chadwick EG, Capparelli EV, Yogev R, et al; P1030 Team. Pharmacokinetics, safety and efficacy of lopinavir /ritonavir in infants less than 6 months of age: 24 week results. AIDS. 2008;22(2):249-255.
10. Jullien V, Urien S, Hirt D, et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother. 2006;50(11):3548-3555. (Pubitemid 44684864)
11. Chadwick EG, Pinto J, Yogev R, et al; International Maternal Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team. Early initiation of lopinavir/ ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J. 2009;28(3):215-219.
12. Urien S, Firtion G, Anderson ST, et al. Lopinavir /ritonavir population pharmacokinetics in neonates and infants. Br J Clin Pharmacol. 2011;71(6):956-960.
13. McArthur MA, Kalu SU, Foulks AR, Aly AM, Jain SK, Patel JA. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J. 2009;28(12):1127-1129.
14. Lopriore E, Rozendaal L, Gelinck LB, Bökenkamp R, Boelen CC, Walther FJ. Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART. AIDS. 2007;21(18):2564-2565. (Pubitemid 350145200)
15. Kaletra (lopinavir/ritonavir): label change: serious health problems in premature babies. US Food and Drug Administration. http://www.fda.gov/Safety/ MedWatch/SafetyInformation/Safety AlertsforHumanMedicalProducts/ucm246167.htm. Accessed March 10, 2011.
16. Blanche S, Rouzioux C, Moscato ML, et al; HIV Infection in Newborns French Collaborative Study Group. A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. N Engl J Med. 1989;320(25):1643-1648. (Pubitemid 19154588)
17. Dhondt JL, Dorche C, Farriaux JP, Courte C. Neonatal screening for congenital adrenal hyperplasia: a pilot study in France. J Inherit Metab Dis. 1986;9(suppl 1):147-151. (Pubitemid 17189784)
18. Benhammou V, Warszawski J, Bellec S, et al; ANRS-Enquête Périnatale Française. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS. 2008;22(16):2165-2177.
19. Forest MG. Adrenal function tests. In: Ranke MB, ed. Diagnostics of Endocrine Function in Children and Adolescents. Basel, Switzerland: Karger; 2003:372-426.
20. de Peretti E, Forest MG. Pattern of plasma dehydroepiandrosterone sulfate levels in humans from birth to adulthood: evidence for testicular production. J Clin Endocrinol Metab. 1978;47(3):572-577. (Pubitemid 9010409)
21. Beal SL, Sheiner LB, ed. NONMEM Users' Guide. San Francisco, CA: NONMEM Project Group;1992.
22. Cavarzere P, Samara-Boustani D, Flechtner I, et al. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol. 2009;161(2):285-292.
23. Gingelmaier A, Kurowski M, Kästner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS. 2006;20(13):1737-1743. (Pubitemid 44299365)
24. Yeh RF, Rezk NL, Kashuba AD, et al. Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women. Antimicrob Agents Chemother. 2009;53(6):2367-2374.
25. Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med. 2009;360(22):2328-2339.
26. Foisy MM, Yakiwchuk EMK, Chiu I, Singh AE. Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008;9(6):389-396. (Pubitemid 352015642)
27. Watterberg KL. Adrenocortical function and dysfunction in the fetus and neonate. Semin Neonatol. 2004;9(1):13-21. (Pubitemid 38112116)
28. Fernandez EF, Watterberg KL. Relative adrenal insufficiency in the preterm and term infant. J Perinatol. 2009;29(suppl 2):S44-S49.
29. Martinerie L, Viengchareun S, Delezoide AL, et al. Low renal mineralocorticoid receptor expression at birth contributes to partial aldosterone resistance in neonates. Endocrinology. 2009;150(9):4414-4424.
30. Martinerie L, Pussard E, Foix-L'Hélias L, et al. Physiological partial aldosterone resistance in human newborns. Pediatr Res. 2009;66(3):323-328.
31. Neary N, Nieman L. Adrenal insufficiency: etiology, diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2010;17(3):217-223.
32. Ozturk IC, Wei WL, Palaniappan L, Rubenfire M, Killeen AA. Analysis of CYP21 coding polymorphisms in three ethnic populations: further evidence of nonamplifying CYP21 alleles among whites. Mol Diagn. 2000;5(1):47-52. (Pubitemid 30165064)
33. White PC; Medscape. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol. 2009;5(9):490-498.
34. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362(24):2282-2294.